about
Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinomaConcurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinomaEmerging therapeutic targets in esophageal adenocarcinomaPreoperative therapy in locally advanced esophageal cancerNeoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational modelPast, current and future protocols for combined modality therapy in childhood medulloblastoma.Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer.The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Future chemotherapy and radiotherapy options in head and neck cancer.Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cellsAdditive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02Concurrent chemotherapy and radiotherapy for head and neck cancer.In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effectsPharmacotherapy of head and neck cancer.Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.Evaluation of an Accelerated Chemoradiotherapy Protocol for Oropharyngeal Squamous Cell Carcinoma in 5 Cats and 3 Dogs.Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.Cisplatin enhances the cytotoxicity of fast neutrons in a murine lymphoma cell line.Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.
P2860
Q24186289-C20A9945-FDB1-4B01-B4F1-2601D609216EQ24201507-2E97E7A0-B70F-4B19-8AB8-D4B8B8546FDBQ26751209-0C53E019-4FC4-4678-8E6A-30F72DC3F0CFQ28070310-34780706-9AB2-43B8-BBF4-17736DFCD1E2Q33387427-B38B1DC3-FEB8-4806-974F-56330A3D91B0Q34844972-B0DFB186-0081-422A-8790-4D1879EE7554Q35070435-B43B563B-F8E8-405E-B744-168054997941Q35297051-42579A7C-F225-47DF-93F6-D193FD78122CQ36142491-780B7A19-E24B-4973-B4C5-CA932443CAA3Q36407462-FE11D02F-8E31-42B8-A3AD-B61C2D9B0092Q36610767-B3C496AB-BDDA-4AE4-8B6B-F4034BA3C08CQ36696568-F3013AD9-0A80-4D76-9ED9-3BFE6C6DDD8FQ36710452-619ED5B1-6A23-42D5-8BC3-9ADD34020758Q37411168-6CA34D76-DA1C-4063-9704-5EBCBA1E5A69Q38611141-D2117C95-7F26-4917-83D6-F52672141660Q38619293-64AE6AF1-F936-46F1-A850-51C89BD269A9Q39018908-F92DBDBA-F672-4964-B51D-F32247756535Q39891019-354A7028-BDB9-4E51-808C-E89B8CC82AC7Q40035482-EED827B5-DE28-4754-9F40-7C9A0929CCBAQ40571935-83C60EF6-42D8-4A0A-AF7D-F5CA89027129Q41778604-9AAD14E7-94F7-4CE5-AEA8-796DDD055169
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Biological basis for chemo-radiotherapy interactions.
@en
type
label
Biological basis for chemo-radiotherapy interactions.
@en
prefLabel
Biological basis for chemo-radiotherapy interactions.
@en
P1476
Biological basis for chemo-radiotherapy interactions.
@en
P2093
C Hennequin
V Favaudon
P304
P356
10.1016/S0959-8049(01)00360-4
P577
2002-01-01T00:00:00Z